Investor Presentaiton slide image

Investor Presentaiton

VGX-3100 Phase 2 Studies in HPV-Associated Vulvar and Anal HSIL/Precancerous Dysplasias • Target HPV 16/18 subtypes; E6/E7 oncogenes TRIALS: VGX-3100 • Treat high-grade squamous intraepithelial lesions (HSIL) Precancerous Vulvar Dysplasia: Interim findings (6 months after start of treatment) 22 Phase 2 open-label study x33 33 women enrolled Interim data reported for 10 Decrease in lesion area: 80% of patients Resolution of vulvar dysplasia: 20% of patients Non-detectability of HPV 16/18: 20% of patients Phase 2 open-label study x23 23 patients enrolled Precancerous Anal Dysplasia: Interim findings (6 months after start of treatment) Clearance of lesions: 50% of patients Interim data reported for 20 Decrease in number of lesions: 75% of patients INOVIO POWERING DNA MEDICINES
View entire presentation